LEADER 01486nam  2200445   450 
001 9910568260903321
005 20221202094642.0
010   $a9783030963767$b(electronic bk.)
010   $z9783030963750
035   $a(MiAaPQ)EBC6986473
035   $a(Au-PeEL)EBL6986473
035   $a(CKB)22371878300041
035   $a(PPN)269149287
035   $a(EXLCZ)9922371878300041
100   $a20221202d2022      uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCancer immunotherapies $esolid tumors and hematologic malignancies /$fPriya Hays, editor
210  1$aCham, Switzerland :$cSpringer International Publishing,$d[2022]
210  4$dİ2022
215   $a1 online resource (322 pages)
225 1 $aCancer Treatment and Research Ser. ;$vv.183
311 08$aPrint version: Hays, Priya Cancer Immunotherapies Cham : Springer International Publishing AG,c2022 9783030963750 
320   $aIncludes bibliographical references.
410  0$aCancer Treatment and Research
606   $aCancer$xImmunotherapy
606   $aCancer$xImmunotherapy$xResearch
615  0$aCancer$xImmunotherapy.
615  0$aCancer$xImmunotherapy$xResearch.
676   $a616.994061
702   $aHays$b Priya$f1968-
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
912   $a9910568260903321
996   $aCancer immunotherapies$92986698
997   $aUNINA